Tests ESG206 against placebo in adults with lupus
Tests the drug ESG206 against a placebo in adults with systemic lupus erythematosus.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Key facts
- Where
- Changde, Changsha, Guilin, Handan, Huzhou, Jinhua, Linfen, Liupanshui, Loudi, Mianyang, Nanchong, Ningbo, Shanghai, Shenzhen, Shijiazhuang, Xuzhou, Zhongshan, Zhuzhou, and Zibo, ChinaSee the 20 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07760155, who can take part
Where in China
- Changde First People's HospitalChangde, ChinaNo longer taking part
- Xiangya Hospital Central South UniversityChangsha, ChinaNo longer taking part
- Second Affiliated Hospital of Guilin Medical UniversityGuilin, ChinaNo longer taking part
- Affiliated Hospital of Hebei Engineering UniversityHandan, ChinaNo longer taking part
- Huzhou third people's HospitalHuzhou, ChinaNo longer taking part
- Jinhua Municipal Central HospitalJinhua, ChinaNo longer taking part
- Linfen Central HospitalLinfen, ChinaNo longer taking part
- Liupanshui Shougang Shuigang HospitalLiupanshui, ChinaNo longer taking part
- Loudi Central HospitalLoudi, ChinaNo longer taking part
- Mianyang Central HospitalMianyang, ChinaNo longer taking part
- Affiliated Hospital of North Sichuan Medical CollegeNanchong, ChinaNo longer taking part
- Ningbo Medical Center Lihuili HospitalNingbo, ChinaNo longer taking part
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
- Shanghai Tongji HospitalShanghai, ChinaNo longer taking part
- Shenzhen Third People's HospitalShenzhen, ChinaNo longer taking part
- Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaNo longer taking part
- Xuzhou Central HospitalXuzhou, ChinaNo longer taking part
- Zhongshan Traditional Chinese Medicine HospitalZhongshan, ChinaNo longer taking part
- Zhuzhou Central HospitalZhuzhou, ChinaNo longer taking part
- Zibo Central hospitalZibo, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Escugen Biotechnology Co., Ltd
- Trial code
- NCT07760155
- Record updated
- 12 August 2026
- Original description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).Read full original descriptionShow less
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).
Inclusion: Adults (≥18 years of age) with a confirmed diagnosis of Systemic Lupus Erythematosus; Evidence of active disease at screening; Willing and able to provide written informed consent.
Exclusion: Prior or recent use of prohibited immunomodulatory therapies; Have other autoimmune diseases that may interfere with the assessment of SLE; Clinically significant infections, malignancies, or uncontrolled medical conditions; Pregnancy or breastfeeding.